Among a slew of lawsuits against drug and medical device companies regarding marketing fraud or kickbacks, doctors aren't penalized for their involvement.
Drugmaker Eli Lilly pleaded guilty to illegally
marketing its antipsychotic Zyprexa for elderly
patients and paid $1.4 billion in criminal
penalties and settlements.
(AP file photo/Darron Cummings)
by Tracy Weber and Charles Ornstein, ProPublica
This story was co-published with the Washington Post
Two years ago, drugmaker Eli Lilly pleaded guilty to illegally marketing its blockbuster antipsychotic Zyprexa for elderly patients. Lilly paid $1.4 billion in criminal penalties and settlements in four civil lawsuits.
But a doctor named as a co-defendant in one suit - for allegedly taking kickbacks to prescribe the drug extensively at nursing homes - never was pursued.
Last year, Alpharma paid $42.5 million to settle federal allegations that it paid kickbacks to doctors to prescribe its painkiller Kadian.
"Health-care decisions must be based solely upon what is best for the individual patient and not on which pharmaceutical company is paying the doctor the biggest kickback," Rod J. Rosenstein, U.S. attorney for the District of Maryland, said in a statement announcing the settlement.
But the doctors accused of trading prescriptions for paid speaking gigs faced no consequences.
At least 15 drug and medical-device companies have paid $6.5 billion since 2008 to settle accusations of marketing fraud or kickbacks. However, none of the more than 75 doctors named as participants were sanctioned, despite allegations of fraud or of conduct that put patients at risk, a review by ProPublica found.
A jury begins deliberations in the 1st trial over DePuy Orthopaedics' Pinnacle metal-on-metal hip...
Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans,...
Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3...
The U.S. Homeland Security Dept. is investigating reports of cybersecurity flaws in medical devices...
Sales of its cardiac rhythm management devices help boost Boston Scientific above expectations for...